In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Theravance: Having Cake and Eating It

Executive Summary

Thanks to productivity, lower-risk follow-on drugs and access to a Big Pharma balance sheet, Theravance is trying to demonstrate the possibility of getting paid for doing what biotech does best: research.
Advertisement

Related Content

Collaborating for Better R&D Productivity
Private Equity Comes to Discovery
20% Solution: Addressing the Biotech/Pharma Logjam with Innovation Partnerships
GSK's Risk-Sharing Deals to Compete with In-House R&D
Theravance/Astellas: Quality Deal but without the Brand Name
Validating Europe's De-Risked Approach
Cytokinetics Stays the Course
The Buzz at JP Morgan--Biopharma: New Models Wanted
Why Early-Stage Dealmaking is Hot
Jumpstart to Products

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002535

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel